Abstract:BACKGROUND Pulmonary arterial hypertension (PAH) is characterized by progressive increase of pulmonary vascular resistance and obliterative pulmonary vascular remodeling that result in right heart hypertrophy, failure and premature death. One of the hallmarks of PAH is vascular fibrosis, an excessive deposition of extracellular matrix components (most notably collagen) in the vessel wall, which has been shown to have an important role in the pathogenesis of severe vascular remodeling. Our goal is to gain a better understanding of the mechanisms underlying pulmonary vascular fibrosis seen in IPAH patients in order to identify potential new drug target(s) to inhibit pulmonary vascular fibrosis and thereby prevent/reverse vascular remodeling for treatment of PAH. METHODS Employing the mice with Tie2 Cre‐mediated deletion of Egln1 which encodes hypoxia‐inducible factor prolyl hydroxylase 2, PHD2 ( Egln1 Tie2Cre ), and double knockout mice with Tie2 Cre‐mediated genetic deletions of both Egln1 and Hif1a (EH1) or Egln1 and Hif2a (EH2), we studied the role of PHD2 deficiency and HIF activation in inducing pulmonary vascular fibrosis. Trichrome staining was used to quantify pulmonary vascular fibrosis. Quantitative RT‐PCR analysis and immunostaining were carried out to define the molecular mechanisms of vascular fibrosis associated with PAH in Egln1 Tie2Cre mice. RESULTS Similar to IPAH lungs, mice inactivated for PHD2 in endothelial cells exhibited obliterative vascular remodeling with massive collagen deposition in the vessel wall as observed in Figure 1A . There was however no marked increase of interstitial fibrosis in Egln1 Tie2 lungs. Intriguingly, pulmonary vascular fibrosis was inhibited by genetic deletion of HIF2α but not HIF1α, suggesting an important role of activation of HIF2α secondary to PHD2 deficiency in mediating pulmonary vascular fibrosis. Quantitative RT‐PCR analysis revealed a marked increase of fibrotic markers such as collagen 1α1, 1α2 and 3α1 in Egln1 Tie2Cre mouse lungs, which was inhibited in EH2 mouse lungs. Another important feature of vascular fibrosis is the presence of myofibroblasts, which are responsible for extracellular matrix (ECM) production and accumulation. Immunostaining demonstrated prominent expression of periostin, a marker for myofibroblasts in Egln1 Tie2Cre mouse lungs. The number of cells co‐stained with α‐smooth muscle actin and periostin was drastically increased in the vessel wall of Egln1 Tie2 mouse lungs. CONCLUSIONS Our results demonstrate that endothelial PHD2 deficiency and resultant activation of HIF2α are responsible for pulmonary vascular fibrosis in the newly discovered mouse model of PAH with obliterative vascular remodeling and progressive right heart failure. We also showed that in vivo PHD2 deletion increases the number of myofibroblasts in the vessel wall. These studies defined an unexpected role of PHD2 deficiency in the mechanisms of vascular fibrosis associated with severe PAH. Thus, targeting PHD2/HIF‐2α signaling is a promising strategy to reverse vascular fibrosis for treatment of severe PAH and promote survival.

Silencing EIF3A ameliorates pulmonary arterial hypertension through HDAC1 and PTEN/PI3K/AKT pathway in vitro and in vivo

Endothelial Progenitor Cells May Inhibit Apoptosis of Pulmonary Microvascular Endothelial Cells: New Insights into Cell Therapy for Pulmonary Arterial Hypertension

EP3 Receptor Deficiency Attenuates Pulmonary Hypertension Through Suppression of Rho/TGF-β1 Signaling

Upregulation of IRF9 Contributes to Pulmonary Artery Smooth Muscle Cell Proliferation During Pulmonary Arterial Hypertension

Ethyl pyruvate alleviates pulmonary arterial hypertension via PI3K-Akt signaling

Plasminogen activator Inhibitor-2 inhibits pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension via PI3K/Akt and ERK signaling

Inhibition of YTHDF1 prevents hypoxia-induced pulmonary artery smooth muscle cell proliferation by regulating Foxm1 translation in an m6A-dependent manner

MiR-193-3p Attenuates the Vascular Remodeling in Pulmonary Arterial Hypertension by Targeting PAK4

eIF2α promotes vascular remodeling via autophagy in monocrotaline-induced pulmonary arterial hypertension rats

MicroRNA‐483 Amelioration of Experimental Pulmonary Hypertension

ERK/Drp1‐dependent mitochondrial fission contributes to HMGB1‐induced autophagy in pulmonary arterial hypertension

Inhibiting HDAC3 (histone Deacetylase 3) Aberration and the Resultant Nrf2 (nuclear Factor Erythroid-Derived 2-Related Factor-2) Repression Mitigates Pulmonary Fibrosis

Decrease in LINC00963 attenuates the progression of pulmonary arterial hypertension via microRNA‐328‐3p/profilin 1 axis

PARM1 Drives Smooth Muscle Cell Proliferation in Pulmonary Arterial Hypertension via AKT/FOXO3A Axis

Farnesyl diphosphate synthase regulated endothelial proliferation and autophagy during rat pulmonary arterial hypertension induced by monocrotaline

Abstract 108: Mediator 1 Regulation of the BMP / TGF-β Signaling in Endothelium: Implications for Pulmonary Hypertension

Abstract 306: Endothelial 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase, Isoform 3 (PFKFB3) Deficiency Inhibits Hypoxia-Induced Pulmonary Hypertension in Mice

Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension

Endothelial 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase, Isoform 3 (PFKFB3) Deficiency Inhibits Hypoxia-Induced Pulmonary Hypertension in Mice

Hif2 Alpha is Required for the Development of Pulmonary Vascular Fibrosis Associated with Pulmonary Arterial Hypertension

Downregulation of PDCD4 through STAT3/ATF6/autophagy mediates MIF-induced PASMCs proliferation/migration and vascular remodeling